Latest Information Update: 12 Dec 2006
At a glance
- Originator Unknown
- Developer Azwell; Nonindustrial source
- Class Anticoagulants
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 23 Sep 1998 No-Development-Reported for Thrombosis in Japan (Unknown route)
- 05 Jun 1996 New profile
- 05 Jun 1996 Preclinical development for Thrombosis in Japan (Unknown route)